ClinicalTrials.gg
Not yet recruitingNCT07951333Updated Nov 20, 2026

Targeted Quality Improvement Trial to Improve Post-Discharge VTE

An observational study in Venous Thromboembolism, Abdominal Cancer Surgery and Pelvic Surgery, sponsored by University of Chicago. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Chicago · Observational

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
80
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 221 studies in Venous Thromboembolism with a site in United States — 37 open to participants now, 40 under way, 8 of them phase 3. Venous Thromboembolism · United States.

Planned enrollment
46th of 56
80 · median 1,094
Started
2027
with 1 other
Observational
56 of 221
12 open now
Primary completion
2028-01
later than 26 of 39 live
Registered
221st of 221
by date

Among the 221 studies in Venous Thromboembolism with a site in United States, this one is the 46th largest by planned enrollment of the 56 observational ones that give a count, is one of 2 that started in 2027, is one of 56 observational ones, reaches primary completion later than 26 of the 39 other live ones, and was the 221st registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

37 of the 221 studies in Venous Thromboembolism with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 221 studies in Venous Thromboembolism with a site in United States, or all of them as a file.
02

Study summary

Venous thromboembolism (VTE) is the most common preventable cause of death after major abdominal and pelvic cancer surgery, and over one-third of events occur after discharge. National guidelines recommend extended post-discharge chemoprophylaxis, but hospital adherence varies widely. This observational study has two parts. Aim 1 uses interviews, focus groups, and surveys with patients, clinicians, and health system stakeholders to identify barriers and facilitators to implementing a post-discharge VTE chemoprophylaxis quality improvement project. Aim 2 uses retrospective hospital- and population-level data and coincidence analysis to identify hospital performance phenotypes and develop targeted implementation strategies. Findings will inform a separately registered stepped-wedge implementation trial (Aim 3).

Read the detailed description

Aim 1: Semi-structured interviews, focus groups, and electronic surveys will be conducted with patients (n≈20) undergoing abdominal or pelvic cancer surgery, clinicians (n≈20), and health system stakeholders (n≈10). Surveys include study-specific VTE chemoprophylaxis and ordering surveys, the Organizational Readiness to Change Assessment (ORCA), and the Safety Attitudes Questionnaire (SAQ). Interviews are audio-recorded, transcribed, de-identified, and analyzed with hybrid inductive and deductive coding mapped to CFIR domains. Patient eligibility is screened through the medical record; screening data are not linked to survey or interview responses.

Aim 2: De-identified, retrospective hospital- and population-level data (demographics, procedure details, VTE prophylaxis orders, VTE outcomes), obtained through the University of Chicago Center for Research Informatics, will be analyzed using coincidence analysis (CNA) to identify causal pathways, define low- and high-performance hospital phenotypes, and develop targeted implementation strategies. Aim 2 data are kept separate from Aim 1 recruitment data.

This record covers Aims 1 and 2 only. The Aim 3 stepped-wedge trial is registered separately

03

Conditions studied

  • Venous Thromboembolism
  • Abdominal Cancer Surgery
  • Pelvic Surgery

Keywords

  • implementation fidelity
  • quality improvement
  • ISQIC
  • CFIR
  • implementation science
  • coincidence analysis
  • post-discharge
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients, clinicians, and health system stakeholders involved in abdominal and pelvic cancer surgery care, plus a retrospective hospital-level dataset.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients: adults (18-85) undergoing abdominal and/or pelvic cancer surgery; English-speaking
  • Clinicians: faculty and fellow physicians, advanced practice providers, physician assistants, medical assistants, dietitians, and social workers in participating surgical service clinics; English-speaking
  • Stakeholders: Chief Medical Officer, Chief Information Officer, Chief Quality Officer, or related leadership

Aim 2: records of patients undergoing abdominal or pelvic cancer surgery between 1/1/2006 and 9/16/2025

Exclusion criteria

Exclusion Criteria:

  • Non-English-speaking individuals
  • Patients not undergoing abdominal or pelvic cancer surgery
  • Individuals under 18
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients

    Adults undergoing abdominal or pelvic cancer surgery at the University of Chicago Medical Center, interviewed or surveyed about post-discharge VTE chemoprophylaxis.

  • Clinicians

    Surgeons, advanced practice providers, nurses, and other clinical staff who care for abdominal and pelvic cancer surgery patients, interviewed or surveyed.

  • Health System Stakeholders

    Chief Medical, Information (or Medical Information), and Quality Officers and related leadership, interviewed.

  • Retrospective Hospital/Patient Dataset (Aim 2)

    De-identified, hospital- and population-level records of abdominal and pelvic cancer surgery patients, 2006-2025

06

What researchers measure

Primary outcomes

  1. Barriers and facilitators to post-discharge VTE chemoprophylaxis implementation

    Themes identified from interviews and focus groups, coded and mapped to CFIR domains

    Time frame: Year 1 and 2; Single interview or focus group session (30-60 minutes), at enrollment.

Secondary outcomes

  1. Organizational readiness to change (ORCA score)

    Survey scores, dichotomized as low or high

    Time frame: Year 1 and 2; Single survey at enrollment.

  2. Safety and quality culture (SAQ score)

    Survey scores, dichotomized as low or high.

    Time frame: Year 1 and 2; Single survey at enrollment.

  3. VTE chemoprophylaxis ordering patterns

    Survey responses on type of prophylaxis prescribed, reasoning, and risk factors.

    Time frame: Year 1 and 2; Single survey at enrollment.

  4. Hospital performance phenotypes

    Number and characteristics of low- and high-performance phenotypes identified by coincidence analysis of Aim 1 and retrospective data.

    Time frame: Year 3; Following AIM 2 completion.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — Qualitative recordings and transcripts will not be shared. De-identified data will be retained in secure University of Chicago storage, and any external sharing would require IRB review

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.

Of 97 non-industry observational studies under Venous Thromboembolism, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's planned 12 months is below that.

Counting every sponsor, half of 118 studies reached it within 45 months; a quarter within 23 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 20, 2026
StartEst.
Jan 2027
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951333
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Ryan Merkow, MS, MD
principal investigator · University of Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion